AgingHealth Care - GeneralPandemic

Moderna’s RSV shot 83.7% effective, late-stage trial shows

By Paige Twentier for Becker’s Hospital Review on January 18, 2023

Moderna’s respiratory syncytial virus vaccine candidate for older adults is about 84 percent effective, its phase 3 study showed, and the company said it will seek approval this year.  Here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or

Leave a Reply